Background: Endoscopic and histologic healing are emerging as new therapeutic
| INTRODUCTION
Anti-tumor necrosis factor (anti-TNF) therapies, particularly infliximab, have revolutionized the treatment of patients with moderateto-severe ulcerative colitis (UC). Objective therapeutic outcomes, such as endoscopic and histologic healing, are currently considered as important target endpoints of anti-TNF therapy in UC, as these have been associated with lower rates of disease relapse, hospitalization and need for colectomy. [1] [2] [3] [4] [5] [6] Reactive therapeutic drug monitoring is emerging as the new standard-of-care for optimizing anti-TNF therapy in inflammatory bowel disease (IBD) . 7 Recent studies have demonstrated that proactive therapeutic drug monitoring of infliximab with drug titration to a therapeutic window is associated with favorable long-term therapeutic outcomes in IBD and may be superior to reactive therapeutic drug monitoring. [8] [9] [10] Moreover, many exposure-response relationship studies have shown that higher serum anti-TNF drug concentrations are associated with better clinical outcomes in IBD, suggesting that it is maybe time to go beyond from a 'treat-to-target' to a 'treat-totrough' therapeutic approch. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Nevertheless, there are only limited data regarding therapeutic drug monitoring in UC and even less data regarding a therapeutic window to target for an important objective outcome, mucosal healing. To our knowledge, there are no data in UC with respect to anti-TNF therapeutic drug monitoring and histologic healing, which represents the ultimate form of mucosal healing.
The primary aim of the study was to investigate the association of serum infliximab trough concentrations during maintenance therapy with endoscopic or histologic healing in patients with moderateto-severe UC. A secondary aim was to identify potential factors related to these therapeutic outcomes. 
| MATERIALS AND METHODS

| Statistical analysis
Descriptive statistics were provided with medians and interquartile range (IQR) for continuous variables and frequencies and percentages for categorical variables. Receiver-operating characteristic (ROC) analyses were performed to identify infliximab trough concentration thresholds associated with endoscopic or histologic healing.
Optimal thresholds were chosen using the Youden index, which maximizes the sum of the specificity and sensitivity of the ROC curve. 16 Sensitivity (SN), specificity (SP), positive predictive value (PPV) and negative predictive value (NPV) were also calculated.
Infliximab trough concentrations during maintenance therapy were compared between groups by a Mann-Whitney U-test. Serum infliximab trough concentrations were categorized also into quartiles.
Rates of endoscopic or histologic healing were compared across infliximab trough concentration quartiles using a chi-square test (linear-by-linear association Forty-five patients had only one endoscopy, eight patients had two endoscopies and three patients had three endoscopies.
Patients' demographic and clinical characteristics are depicted in Table 1 .
| Infliximab trough concentration and endoscopic healing
Endoscopic healing was found in 31/70 (44%) of colonoscopies.
Serum infliximab trough concentration was statistically significantly higher in patients with endoscopic healing compared to those without (Figure 1) . The relationship between infliximab trough concentration and endoscopic healing was further analyzed by dividing infliximab trough concentrations into quartiles. The higher infliximab trough concentration quartiles were associated with statistically significantly higher rates of endoscopic healing ( Figure 2 ). Factors associated with the lowest quartile of infliximab trough concentration during maintenance therapy were male gender, low serum albumin levels, elevated serum CRP levels (>5 mg/L) and ATI positivity (Table S1 ). ROC analysis identified an infliximab trough concentration threshold of 7.5 lg/mL to be statistically significantly associated with endoscopic healing (SN 77%; SP 62%; PPV 62%; NPV 77%) ( Figure 3A) . In multivariable analysis, infliximab trough concentration ≥ 7.5 lg/mL was identified as the only variable independently associated with endoscopic healing [OR 4.3 (95% CI 1.4-13.3), P = .013] (Table 2A) . Based on incremental gain analysis, we identified an infliximab trough concentration therapeutic window of 12-15 lg/mL to be associated with an endoscopic healing rate over 70%, although the rate continued to increase beyond this threshold range ( Figure 4A ). (Table 2A) . Based on incremental gain analysis, no plateau for histologic healing by infliximab trough concentration was reached, and only at infliximab trough concentration above 15 lg/ mL did histologic healing rates exceed 70% ( Figure 4B ).
| DISCUSSION
This multi-center retrospective cohort study demonstated that higher infliximab trough concentrations during maintenance therapy were associated with endoscopic and histologic healing in patients with moderate-to-severe UC. To date, this is the largest study evaluating the association between anti-TNF concentrations and mucosal healing in UC. More importantly, to our knowledge this study is the first to investigate anti-TNF drug concentrations for the endpoint of histologic healing. Specifically, infliximab trough concentration thresholds of 7.5 and 10.5 lg/mL were found to be independently associated with endoscopic and histologic healing, respectively, with even higher concentrations associated with more desirable rates of both endoscopic and histologic healing. were needed to achieve a mucosal healing rate of 80-90% in patients with IBD. 14 We observed that higher infliximab trough concentrations of at least 12-15 lg/mL were associated with endoscopic healing in over 70% of UC patients. These values are somewhat higher than those reported by Ungar et al 14 with the potential for fecal loss of infliximab. [24] [25] [26] [27] Similarly, higher infliximab concentrations were associated with healing in perianal fistulizing CD, as Yarur et al identified an infliximab trough concentration cut-off of ≥10.1 lg/mL associated with fistula healing and proposed that even higher concentrations (>20.2 lg/mL) must be targeted before changing to other therapeutic options. 19 Also of importance in our study is that the rates of endoscopic healing did not reach a plateau with respect to increasing infliximab trough concentrations and instead continued to increase with higher drug concentrations. One explanation is that higher concentrations may be required for some patients to attain this objective endpoint. It is also possible, however, that a more healed mucosa allows for the attainment of higher infliximab concentrations.
A novel aspect of our study was establishing an association between infliximab concentrations and histologic healing. In fact, we identified that infliximab trough concentrations associated with histologic healing were numerically higher than those associated with endoscopic healing and also that fairly high infliximab concentrations (>15 lg/mL) were associated with more satisfactory rates of histologic healing above 70%. As with mucosal healing, the rates of histologic healing did not reach a plateau with respect to increasing infliximab trough concentrations and continued to increase with higher drug concentrations, which again implyies either that higher concentrations may be required for certain patients to attain this most rigorous endpoint or that attainment of this more rigorous endpoint allows for higher infliximab concentrations to be achieved. The totality of the evidence to date thus seems to indicate that while higher infliximab trough concentrations are associated with clinical response/remission in IBD, even higher concentrations are associated with more objective endpoints of biochemical remission or mucosal healing, with the highest concentrations associated with the most difficult objective endpoints of fistula healing or histologic healing. 13, 14, 17, 19 In this study, several factors were identified to be associated with low infliximab trough concentration quartiles during maintenance therapy: male gender, a higher disease activity (lower serum albumin, elevated serum CRP) and ATI. These variables have been previously shown to associate with a rapid clearance of anti-TNF drugs. [27] [28] [29] Limitations of this study include its retrospective nature and the lack of central reading of endoscopies. However, the overwhelming majority of endoscopies included in this study were performed by experts in IBD. The definition of histologic healing used in this study was selected based on simplicity and clinical relevance, as no histologic index available for UC has been developed via a formal F I G U R E 4 Incremental gain in endoscopic (A) and histologic (B) healing rates in relation to serum infliximab trough concentrations during maintenance therapy in patients with moderate-to-severe ulcerative colitis. Increments of 3 lg/mL infliximab trough concentration were used to define the range of maximal increase in the rate of endoscopic or histologic healing with any increase in drug concentration during maintenance therapy. P-value (chi-square test, linear-by-linear association)
T A B L E 2 Variables associated with endoscopic (A) and histologic (B) healing in patients with moderate-to-severe ulcerative colitis treated with infliximab In conclusion, this study indicates that relatively high infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in patients with moderate-tosevere UC, and importantly that infliximab trough concentrations may vary depending on the therapeutic outcome of interest. Nevertheless, before incorporating these results into therapeutic algorithms, large prospective longitudinal studies are warranted to establish causality between higher anti-TNF drug concentrations and objective therapeutic outcomes in IBD.
